Novo Nordisk's Market Surge

This chapter explores the rise in Novo Nordisk's shares linked to the recent FDA approval of their weight loss drug Wagovi and the diabetes medication Ozempic. It also covers the accessibility strategies for these medications and briefly touches on current events including the crisis in Gaza and political updates.